CEO Michael Pellini, MD, calls the transformational billion-dollar-plus deal his company, Foundation Medicine Inc., inked with Roche in January 2015, “an opportunity to both broaden the existing business and, for the first time, think about incorporating additional assets.”
The backing of Roche, now a majority shareholder thanks to a $1 billion investment, gives Foundation Medicine options as it rides the wave of genomic interpretation in oncology enabled by...